secwatch.observer — SEC 8-K summary
======================================

Issuer:     PUMA BIOTECHNOLOGY, INC. (PBYI)
CIK:        0001401667
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001437749-22-025761
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Puma Biotechnology Q3 net loss narrows to $0.4M; raises FY 2022 NERLYNX revenue guidance
--------------------------------------------------------------------------------

- Q3 product revenue $54.3M, up 25% YoY from $43.4M; net loss $0.4M ($0.01/share) vs $44.7M loss in Q3 2021.
- Non-GAAP adjusted net income $2.5M ($0.05/share) vs adjusted loss of $40.4M a year ago.
- Raises FY 2022 product revenue guidance to $194-$196M from prior $180-$190M; net income guidance $7-$9M.
- In-licensed alisertib (aurora kinase A inhibitor) from Takeda for $7M upfront; plans initial trials in HR+ breast cancer and small cell lung cancer.
- Cash and marketable securities $78.0M at Sep 30, 2022; operating cash flow $17.3M in Q3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401667/000143774922025761/0001437749-22-025761-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401667/000143774922025761/pbyi20221101_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-22-025761

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer